

Form PTO-1449 JAN 13 2005 U.S. Department of Commerce Patent and Trademark Office

INFORMATION DISCLOSURE STATEMENT  
(Use several sheets if necessary)

<b>Application Number</b>	10/618,179
<b>Filing Date</b>	July 11, 2003
<b>First Named Inventor</b>	Bernard F. Erlanger
<b>Art Unit</b>	1626
<b>Examiner Name</b>	G.M. Shameem
<b>Attorney Docket No.</b>	64081/JPH/AJM/MVM

[illegible][illegible]

Li Shiy

9/12/2005

\***EXAMINER:** Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds of Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English Language Translation is attached.

Applicant: Bernard F. Erlanger et al.  
U.S. Serial No.: 10/618,179  
Filed: July 11, 2003  
Exhibit A

<b>Form PTO-1449</b> <b>U.S. Department of Commerce</b> <b>Patent and Trademark Office</b>  <b>INFORMATION DISCLOSURE CITATION</b> (Use several sheets if necessary)	Application Number	10/618,179
	Filing Date	July 11, 2003
	First Named Inventor	Bernard F. Erlanger
	Art Unit	1626
	Examiner Name	G.M. Shameem
	Attorney Docket No.	64081/JFW/AJM/MVM

### NON PATENT LITERATURE DOCUMENTS

Examiner Initials <sup>1</sup>	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
LW	4	Avrameas, A. et al. (1998) "Polyreactive anti-DNA monoclonal antibodies and a derived peptide as vectors for the intracytoplasmic and intranuclear translocation of macromolecules," <i>Proc. Natl. Acad. Sci. USA</i> 95: 5601-5606;	
	5	Awwad, M. et al. (1994) "Modification of monoclonal antibody carbohydrates by oxidation, conjugation, or deoxymannojirimycin does not interfere with antibody effector functions," <i>Cancer Immunol. Immunother.</i> 38: 23-30;	
	6	Braden, B.C. et al. (2000) "X-ray crystal structure of an anti-Buckminsterfullerene antibody Fab fragment: Biomolecular recognition of C <sub>60</sub> ," <i>Proc. Natl. Acad. Sci. USA</i> 97: 12193-12197;	
	7	Buschle, M. et al. (1997) "Transloading of tumor antigen-derived peptides into antigen-presenting cells," <i>Proc. Natl. Acad. Sci. USA</i> 94: 3256-3261;	
	8	Chen, B.-X. et al. (1998) "Antigenicity of fullerenes: Antibodies specific for fullerenes and their characteristics," <i>Proc. Natl. Acad. Sci. USA</i> 95: 10809-10813;	
	9	Fawell, S. et al. (1994) "Tat-mediated delivery of heterologous proteins into cells," <i>Proc. Natl. Acad. Sci. USA</i> 91: 664-668;	
	10	Koren, E. et al. (1995) "Murine and human antibodies to native DNA that cross-react with the A and D SnRNP polypeptides cause direct injury of cultured kidney cells," <i>J. Immunol.</i> 154: 4857-4864;	
	11	Lewin, M. et al. (2000) "Tat peptide-derivatized magnetic nanoparticles allow in vivo tracking and recovery of progenitor cells," <i>Nature Biotechnology</i> 18: 410-414;	
	12	Lundberg, M. et al. (2001) "Is VP22 nuclear homing an artifact?," <i>Nature Biotechnology</i> 19: 713;	
	13	Ma, J. et al. (1991) "Antibody penetration of viable human cells. I. Increased penetration of human lymphocytes by anti-RNP IgG," <i>Clin. Exp. Immunol.</i> 84: 83-91;	
	14	Mitchell, D.J. et al. (2000) "Polyarginine enters cells more efficiently than other polycationic homopolymers," <i>J. Peptide Res.</i> 56: 318-325;	
↓	15	Rodwell, J.D. et al. (1986) "Site-specific covalent modification of monoclonal antibodies: In vitro and in vivo evaluations," <i>Proc. Natl. Acad. Sci. USA</i> 83: 2632-2636;	

 EXAMINER  
SIGNATURE

DATE CONSIDERED 9/12/05

\*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a checkmark here if English language Translation is attached.

<b>Form PTO-1449</b> <b>U.S. Department of Commerce</b> <b>Patent and Trademark Office</b>  <b>INFORMATION DISCLOSURE CITATION</b> (Use several sheets if necessary)	Application Number	10/618,179
	Filing Date	July 11, 2003
	First Named Inventor	Bernard F. Erlanger
	Art Unit	1626
	Examiner Name	G.M. Shameem
	Attorney Docket No.	64081/JPH/AJM/MVM

### NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
LW	16	Rothbard, J.B. et al. (2000) "Conjugation of arginine oligomers to cyclosporin A facilitates topical delivery and inhibition of inflammation," <i>Nature Medicine</i> 6: 1253-1257;	
	17	Sutton, B.J. et al. (1983) "The three-dimensional structure of the carbohydrate within the Fc fragment of immunoglobulin G," <i>Biochem. Soc. Trans.</i> 11: 130-132; and	
↓	18	Wender, P.A. et al. (2000) "The design, synthesis, and evaluation of molecules that enable or enhance cellular uptake: Peptoid molecular transporters," <i>Proc. Natl. Acad. Sci. USA</i> 97: 13003-13008.	

 EXAMINER  
 SIGNATURE 

DATE CONSIDERED

9/12/05

\*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a checkmark here if English language Translation is attached.